Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
Provided By GlobeNewswire
Last update: Jun 17, 2025
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached -
Read more at globenewswire.com5.46
+0.09 (+1.68%)
Find more stocks in the Stock Screener
IMRX Latest News and Analysis
